{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:59:53Z","timestamp":1790017193592,"version":"4.0.1"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2019-0040_s_999_w2aab3b7c89b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) is the main common cause of chronic liver disease. The aim of this study is to evaluate the effect of Shilajit, a medicine of Ayurveda, on the liver damage caused by NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0040_s_998_w2aab3b7c89b1b6b1aab1c14b2Aa\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Forty male Wistar rats, after being established as fatty liver models by feeding a high-fat diet (HFD, 12 weeks), were divided randomly into five groups as follows: control (standard diet), vehicle (HFD + distilled water), high-dose Shilajit (HFD + 250 mg\/kg Shilajit), low-dose Shilajit (HFD + 150 mg\/kg Shilajit) and pioglitazone (HFD + 10 mg\/kg pioglitazone). The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), glucose and liver glutathione peroxidase (GPx), superoxide dismutase (SOD) activity, malondialdehyde (MDA) levels, liver weight, and histopathological manifestation outcomes were measured after the 2-week intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0040_s_997_w2aab3b7c89b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Shilajit treatment significantly reduced the values of AST and ALT, TG, TC, LDL, glucose, liver weight, and steatosis, and instead, increased high-density lipoprotein (HDL) compared with the vehicle group (p &lt; 0.05). Further, Shilajit treatment improved the adverse effects of HFD-induced histopathological changes in the liver as compared with the vehicle group (p &lt; 0.001). MDA level and GPx activity increased but SOD activity decreased in the vehicle group compared with the control group (p &lt; 0.05), while treatment with Shilajit restored the antioxidant\/oxidant balance toward a significant increase in the antioxidant system in the Shilajit group (p &lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0040_s_996_w2aab3b7c89b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that Shilajit improved the histopathological NAFLD changes in the liver and indicated the potential applicability of Shilajit as a potent agent for NAFLD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2019-0040","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T04:01:10Z","timestamp":1581652870000},"source":"Crossref","is-referenced-by-count":11,"title":["Hepatoprotective effects of Shilajit on high  fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats"],"prefix":"10.1515","volume":"41","author":[{"given":"Baran","family":"Ghezelbash","sequence":"first","affiliation":[{"name":"Afzalipour School of Medicine , Kerman University of Medical Sciences , Kerman , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Shahrokhi","sequence":"additional","affiliation":[{"name":"Physiology Research Center, Kerman University of Medical Sciences , Kerman 7616914115, Iran , Phone: +989131420391, Fax: +983433257581"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Khaksari","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Research Center , Kerman University of Medical Sciences , Kerman , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouz","family":"Ghaderi-Pakdel","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine , Urmia University of Medical Sciences , Urmia , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Asadikaram","sequence":"additional","affiliation":[{"name":"Neuroscience Research Center, Institute of Neuropharmacology , Kerman , Iran"},{"name":"Department of Biochemistry , Kerman University of Medical Sciences , Kerman , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"2025121207292951063_j_hmbci-2019-0040_ref_001_w2aab3b7c89b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.","DOI":"10.1186\/s12916-017-0806-8"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_002_w2aab3b7c89b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Farrell GC, Wong VW, Chitturi S. NAFLD in Asia \u2013 as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307\u201318.","DOI":"10.1038\/nrgastro.2013.34"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_003_w2aab3b7c89b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease\u2013meta-analytic assessment of prevalence, incidence and outcomes. Hepatology.  2016;64:1388-9.","DOI":"10.1002\/hep.28584"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_004_w2aab3b7c89b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17(Suppl):S186\u201390.","DOI":"10.1046\/j.1440-1746.17.s1.10.x"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_005_w2aab3b7c89b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016;8:75.","DOI":"10.4137\/CMT.S18885"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_006_w2aab3b7c89b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Yki-Jarvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104\u201311.","DOI":"10.1007\/s00125-016-3944-1"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_007_w2aab3b7c89b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874\u201382.","DOI":"10.1002\/hep.24268"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_008_w2aab3b7c89b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865\u201373.","DOI":"10.1002\/hep.21327"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_009_w2aab3b7c89b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635\u201343.","DOI":"10.1038\/35007508"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_010_w2aab3b7c89b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Kopelman PG, Finer N. Reply: is obesity a disease? Int J Obes Relat Metab Disord. 2001;25:1405\u20136.","DOI":"10.1038\/sj.ijo.0801791"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_011_w2aab3b7c89b1b6b1ab2b2c11Aa","unstructured":"Sharma P, Jha J, Shrinivas V, Dwivedi LK, Suresh P, Sinha M. Shilajit: evalution of its effects on blood chemistry of normal human subjects. Anc Sci Life. 2003;23:114\u20139."},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_012_w2aab3b7c89b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK. Shilajit: a review. Phytother Res. 2007;21:401\u20135.","DOI":"10.1002\/ptr.2100"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_013_w2aab3b7c89b1b6b1ab2b2c13Aa","unstructured":"Gangwar SS, Thakur R, Sharma R, Tilak A. Shilajit a medicinal mystery to cure the un-cure disease. Imperial J Interdisciplinary Res. 2016;3:1544\u20137."},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_014_w2aab3b7c89b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Stohs SJ. Safety and efficacy of shilajit (mumie, moomiyo). Phytother Res. 2014;28:475\u20139.","DOI":"10.1002\/ptr.5018"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_015_w2aab3b7c89b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Goel RK, Banerjee RS, Acharya SB. Antiulcerogenic and antiinflammatory studies with shilajit. J Ethnopharmacol. 1990;29:95\u2013103.","DOI":"10.1016\/0378-8741(90)90102-Y"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_016_w2aab3b7c89b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Intern. 2007;27:708\u201315.","DOI":"10.1111\/j.1478-3231.2007.01497.x"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_017_w2aab3b7c89b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","DOI":"10.1002\/hep.20701"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_018_w2aab3b7c89b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the World. Clin Liver Dis. 2016;20:205\u201314.","DOI":"10.1016\/j.cld.2015.10.001"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_019_w2aab3b7c89b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Ji J, Zhang L, Wang P, Mu YM, Zhu XY, Wu YY, et al. Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture. Exp Toxicol Pathol. 2005;56:369\u201376.","DOI":"10.1016\/j.etp.2005.02.003"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_020_w2aab3b7c89b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21:219\u201323.","DOI":"10.1054\/clnu.2001.0529"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_021_w2aab3b7c89b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:360\u20139.","DOI":"10.1055\/s-0028-1091980"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_022_w2aab3b7c89b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010;52:586\u201393.","DOI":"10.1016\/j.jhep.2010.01.003"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_023_w2aab3b7c89b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732\u20137.","DOI":"10.2337\/diacare.21.5.732"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_024_w2aab3b7c89b1b6b1ab2b2c24Aa","unstructured":"Ghosal S, Bhattacharya SK. Antioxidant defense by native and processed shilajit \u2013 a comparative study. Indian J Chem. 1996;35B:127\u201332."},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_025_w2aab3b7c89b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Tripathi YB, Shukla S, Chaurasia S, Chaturvedi S. Antilipid peroxidative property of Shilajit. Phytother Res. 1996;10:269\u201370.","DOI":"10.1002\/(SICI)1099-1573(199605)10:3<269::AID-PTR817>3.0.CO;2-3"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_026_w2aab3b7c89b1b6b1ab2b2c26Aa","unstructured":"Trivedi N, Mazumdar B, Bhatt J, Hemavathi K. Effect of shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats. Indian J Pharmacol. 2004;36:373."},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_027_w2aab3b7c89b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009;50:1217\u201326.","DOI":"10.1002\/hep.23126"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_028_w2aab3b7c89b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Kececi M, Akpolat M, Gulle K, Gencer E, Sahbaz A. Evaluation of preventive effect of shilajit on radiation-induced apoptosis on ovaries. Arch Gynecol Obstet. 2016;293:1255\u201362.","DOI":"10.1007\/s00404-015-3924-6"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_029_w2aab3b7c89b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Bhattacharya SK, Sen AP, Ghosal S. Effects of shilajit on biogenic free radicals. Phytotherapy Res. 1995;9:56\u20139.","DOI":"10.1002\/ptr.2650090113"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_030_w2aab3b7c89b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Jarukamjorn K, Jearapong N, Pimson C, Chatuphonprasert W. A high-fat, high-fructose diet induces antioxidant imbalance and increases the risk and progression of nonalcoholic fatty liver disease in mice. Scientifica. 2016;2016.","DOI":"10.1155\/2016\/5029414"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_031_w2aab3b7c89b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Ismail NA, Okasha SH, Dhawan A, Abdel-Rahman AO, Shaker OG, Sadik NA. Antioxidant enzyme activities in hepatic tissue from children with chronic cholestatic liver disease. Saudi J Gastroenterol. 2010;16:90.","DOI":"10.4103\/1319-3767.61234"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_032_w2aab3b7c89b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Crawford A, Coombes JS, Kunde DA, Ahuja KD, Robertson LK, Ball MJ, et al. Glutathione peroxidase, superoxide dismutase and catalase activities in children with chronic hepatitis. Adv Biosci Biotechnol.  2011;26:2806\u201313.","DOI":"10.1093\/ndt\/gfq828"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_033_w2aab3b7c89b1b6b1ab2b2c33Aa","unstructured":"Chrobot AM, Szaflarska-Szczepanik A, Drewa G. Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit. 2000;6:713\u20138."},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_034_w2aab3b7c89b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527\u2013605.","DOI":"10.1152\/physrev.1979.59.3.527"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_035_w2aab3b7c89b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54:287\u201393.","DOI":"10.1016\/j.ajme.2017.09.001"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_036_w2aab3b7c89b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Carrasco-Gallardo C, Guzman L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142.","DOI":"10.1155\/2012\/674142"},{"key":"2025121207292951063_j_hmbci-2019-0040_ref_037_w2aab3b7c89b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther. 2004;3:333\u201341.","DOI":"10.1177\/1534735404270578"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/hmbci\/41\/1\/article-20190040.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0040\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0040\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:50:33Z","timestamp":1765529433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0040\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,29]]},"published-print":{"date-parts":[[2020,3,26]]}},"alternative-id":["10.1515\/hmbci-2019-0040"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2019-0040","relation":{},"ISSN":["1868-1891"],"issn-type":[{"value":"1868-1891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"article-number":"20190040"}}